Target intelligence / Profile preview

Nuclear factor kappa-light-chain-enhancer of activated B cells, Mitogen-activated protein kinase kinase 1 and 2, Extracellular signal-regulated kinase, and Reactive oxygen species-sensitive pathways (NF-κB/MEK/ERK/ROS network)

Target
NF-κB/MEK/ERK/ROS network
Molecular classification
Transcription factor, Kinase, Enzyme, Signaling network
01

Overview

The NF-κB, MEK1/2–ERK, and ROS-sensitive pathways constitute a highly integrated signaling network that governs cellular responses to environmental stress, cytokines, and growth factors (Oeckinghaus & Ghosh, 2009 [1]; McCubrey et al., 2007 [2]). Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a family of transcription factors essential for regulating genes involved in immunity, inflammation, and the prevention of apoptosis (Oeckinghaus & Ghosh, 2009 [1]). The MEK1/2–ERK cascade, part of the broader Mitogen-Activated Protein Kinase (MAPK) pathway, primarily drives cell proliferation, differentiation, and survival (McCubrey et al., 2007 [2]). Reactive Oxygen Species (ROS) act as secondary messengers that can activate these pathways through the oxidation of signaling proteins or by inactivating inhibitory phosphatases (Morgan & Liu, 2011 [3]). In many pathological conditions, particularly cancer and chronic inflammation, these pathways are constitutively active, leading to uncontrolled cell growth and resistance to therapy (McCubrey et al., 2007 [2]). Crosstalk between these systems allows cells to adapt to oxidative stress, often utilizing NF-κB and ERK to upregulate antioxidant defenses and pro-survival proteins (Morgan & Liu, 2011 [3]). Pharmacological intervention typically targets specific nodes within this network, such as MEK1/2 inhibitors for BRAF-mutant cancers or proteasome inhibitors to block NF-κB activation in multiple myeloma (Oeckinghaus & Ghosh, 2009 [1]; McCubrey et al., 2007 [2]). However, the complexity and redundancy of these pathways often lead to the development of drug resistance, necessitating combination therapies that hit multiple points in the network. Sources: [1] Oeckinghaus A, Ghosh S. Cold Spring Harb Perspect Biol. 2009;1(4):a000034. [2] McCubrey JA, et al. Leukemia. 2007;21(6):1072-1103. [3] Morgan MJ, Liu ZG. Cell Res. 2011;21(1):103-115.

Other names
NF-kappaB signalingMAPK/ERK pathwayROS-mediated stress responseSurvival and stress signaling networkNF-kB/MEK/ERK/ROS axis
02

Mechanism of action

Inhibition of MEK1/2 kinase activity, inhibition of the 26S proteasome to prevent IκB degradation and subsequent NF-κB nuclear translocation, and modulation of cellular redox status through antioxidant or pro-oxidant mechanisms.

03

Biological functions

Signal transductionCell survivalInflammationCell proliferationApoptosisStress response
04

Disease associations

CancerInflammationAutoimmune diseaseNeurodegenerative diseaseCardiovascular disease
05

Safety considerations

Immunosuppression and increased infection riskCardiotoxicity (e.g., decreased LVEF)Peripheral neuropathyDermatologic toxicity (e.g., acneiform rash)Gastrointestinal toxicity (e.g., diarrhea)Potential for paradoxical pathway activation
06

Interacting drugs

Bortezomib

7 more in the full profile.

07

Biomarkers

Phospho-ERK1/2 (p-ERK)NF-κB p65 nuclear translocationIκBα protein levelsIntracellular ROS concentration (e.g., DCFDA staining)

Beyond the preview

Go deeper on Nuclear factor kappa-light-chain-enhancer of activated B cells, Mitogen-activated protein kinase kinase 1 and 2, Extracellular signal-regulated kinase, and Reactive oxygen species-sensitive pathways (NF-κB/MEK/ERK/ROS network).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuclear factor kappa-light-chain-enhancer of activated B cells, Mitogen-activated protein kinase kinase 1 and 2, Extracellular signal-regulated kinase, and Reactive oxygen species-sensitive pathways (NF-κB/MEK/ERK/ROS network).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call